Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ethics code global harmonization

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed and Eucomed ink an agreement May 4 to work together to encourage device associations in other countries to adopt ethics codes that are harmonized with the basic principles of the AdvaMed and Eucomed codes (1"The Gray Sheet" Oct. 19, 2009). The two groups will also seek to bring medical specialty societies in Europe on board with the basic principles of the AdvaMed and Eucomed codes, says AdvaMed General Counsel Christopher White

You may also be interested in...



AdvaMed Delegates Go To China; Business Ethics Code In The Works

AdvaMed and Chinese device makers agreed to harmonize China's standards for ethical business practices with AdvaMed's code of ethics and other international policies in a memorandum of understanding signed earlier this month

Eucomed Releases Framework To Facilitate Compliance With Ethics Code

Eucomed is establishing separate committees to assist member associations with developing and complying with the group's 1Code of Business Practice under a procedural framework adopted Oct. 8

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel